| 1 | highest | 11,480 |
| 2 | lowest | 4,890 |
| 3 | slowest | 66 |
| 4 | tensin | 49 |
| 5 | ed₅₀ | 16 |
| 6 | brillouin | 15 |
| 7 | subventricular | 14 |
| 8 | c3-c4 | 12 |
| 9 | subgranular | 9 |
| 10 | cross-plane | 7 |
| 11 | lv-pv | 7 |
| 12 | medif | 7 |
| 13 | post-combustion | 7 |
| 14 | cpg-slope | 6 |
| 15 | quasi-steady-state | 6 |
| 16 | bølling-allerød | 5 |
| 17 | mid-papillary | 5 |
| 18 | preresponse | 5 |
| 19 | -3826 | 4 |
| 20 | euphotic | 4 |
| 21 | immunotype | 4 |
| 22 | interdiffusion | 4 |
| 23 | no-observed-effect | 4 |
| 24 | sgc-α1 | 4 |
| 25 | t/h12.5 | 4 |
| 26 | 0.4-g/kg | 3 |
| 27 | 24-atom | 3 |
| 28 | endotoxemia-induced | 3 |
| 29 | first-limiting | 3 |
| 30 | hsp110/sse | 3 |
| 31 | indole-3-carbinol-induced | 3 |
| 32 | larmor | 3 |
| 33 | mglu2/3r | 3 |
| 34 | mp2/aug-cc-pvtz | 3 |
| 35 | part-per-billion | 3 |
| 36 | post-fibroscan | 3 |
| 37 | rs11466285 | 3 |
| 38 | t6-t4 | 3 |
| 39 | ttgghi | 3 |
| 40 | within-school | 3 |
| 41 | β3a | 3 |
| 42 | 'gray | 2 |
| 43 | 'macular | 2 |
| 44 | 0.05mg/kg/day | 2 |
| 45 | 1.5+/-1.2 | 2 |
| 46 | 1600-mg | 2 |
| 47 | 22-mcg | 2 |
| 48 | 23k4 | 2 |
| 49 | 49-μg | 2 |
| 50 | 5,5'-disubstituted | 2 |
| 51 | 500-nmol | 2 |
| 52 | 7.5-g | 2 |
| 53 | 800-microg | 2 |
| 54 | 9mg/kg | 2 |
| 55 | ahr-agonists | 2 |
| 56 | alpha2delta | 2 |
| 57 | b3lyp-td | 2 |
| 58 | b3lyp/6-311++g** | 2 |
| 59 | b3lyp/6-311+g**//b3lyp/6-31+g* | 2 |
| 60 | blood-pool-corrected | 2 |
| 61 | cell’s | 2 |
| 62 | cheongdang | 2 |
| 63 | coral-dinoflagellate | 2 |
| 64 | cyp75a | 2 |
| 65 | delipidated | 2 |
| 66 | densu | 2 |
| 67 | e1α | 2 |
| 68 | farman | 2 |
| 69 | femtomole | 2 |
| 70 | fl-ghr | 2 |
| 71 | highest-use | 2 |
| 72 | hipec-mediated | 2 |
| 73 | hospital-facility | 2 |
| 74 | in-tegration | 2 |
| 75 | itz-hpmcas | 2 |
| 76 | kaplan-meier-predicted | 2 |
| 77 | mdr1a | 2 |
| 78 | median-adjusted | 2 |
| 79 | melastatin-related | 2 |
| 80 | mid-to-peripheral | 2 |
| 81 | minus-hybrid | 2 |
| 82 | neuroenergetic | 2 |
| 83 | optetrak | 2 |
| 84 | pam50-based | 2 |
| 85 | physician-specified | 2 |
| 86 | post-to-pre-urinary | 2 |
| 87 | psl-induced | 2 |
| 88 | region-level | 2 |
| 89 | s2p | 2 |
| 90 | spounavirinae | 2 |
| 91 | squid-vibrio | 2 |
| 92 | tiss-28 | 2 |
| 93 | trinational | 2 |
| 94 | undersaturated | 2 |
| 95 | visian | 2 |
| 96 | whole-year | 2 |
| 97 | within-assay | 2 |
| 98 | within-each-population | 2 |
| 99 | α-ktx15 | 2 |
| 100 | 'intelligence | 1 |
| 101 | 0.05-alpha | 1 |
| 102 | 0.10-mg/kg/d | 1 |
| 103 | 0.5-mg-per-kilogram | 1 |
| 104 | 0.50-mg/kg | 1 |
| 105 | 0.8mg | 1 |
| 106 | 1.0-mg-per-kilogram | 1 |
| 107 | 1.0-microg/kg | 1 |
| 108 | 1.2-ml | 1 |
| 109 | 10.3mm | 1 |
| 110 | 100-mg/day | 1 |
| 111 | 100-mug | 1 |
| 112 | 1100-mbq | 1 |
| 113 | 12-μg | 1 |
| 114 | 15-micrograms | 1 |
| 115 | 16-g | 1 |
| 116 | 160-μg | 1 |
| 117 | 2-g/day | 1 |
| 118 | 2.0-mg-per-kilogram | 1 |
| 119 | 2.89σ | 1 |
| 120 | 20-150-mg | 1 |
| 121 | 20-μg/kg | 1 |
| 122 | 200-mg/week | 1 |
| 123 | 22-μg | 1 |
| 124 | 24-mg/day | 1 |
| 125 | 24-μg | 1 |
| 126 | 25-kbq/kg | 1 |
| 127 | 25-microgram | 1 |
| 128 | 3-9mg/kg | 1 |
| 129 | 3.1-mg | 1 |
| 130 | 3.9-g/d | 1 |
| 131 | 30-unit | 1 |
| 132 | 300-mg/week | 1 |
| 133 | 300-microg | 1 |
| 134 | 380-µg/ml | 1 |
| 135 | 4.8-g/d | 1 |
| 136 | 40-μg/kg | 1 |
| 137 | 400-mg-qd | 1 |
| 138 | 400-mgi/kg | 1 |
| 139 | 420-µg/ml | 1 |
| 140 | 44-mcg | 1 |
| 141 | 44-μg | 1 |
| 142 | 45-μg/week | 1 |
| 143 | 5-ht₃b | 1 |
| 144 | 50-db | 1 |
| 145 | 50-kbq/kg | 1 |
| 146 | 50-ng | 1 |
| 147 | 5th-percentile | 1 |
| 148 | 60-minute/week | 1 |
| 149 | 60-μg/kg | 1 |
| 150 | 7777 | 1 |
| 151 | 800-µg | 1 |
| 152 | 9-mg/d | 1 |
| 153 | 9-mg/kg | 1 |
| 154 | 90-μg/week | 1 |
| 155 | 90mg/day | 1 |
| 156 | 95th-percentile | 1 |
| 157 | a4β2 | 1 |
| 158 | alerted/reaching | 1 |
| 159 | alpha-adrenoceptor-like | 1 |
| 160 | alpha2delta-1 | 1 |
| 161 | amol-fmol | 1 |
| 162 | anti-epsilon | 1 |
| 163 | anti-eta | 1 |
| 164 | anti-zeta | 1 |
| 165 | apamin-blockable | 1 |
| 166 | arb-fdc | 1 |
| 167 | asthma-mortality | 1 |
| 168 | b*44:02 | 1 |
| 169 | b3lyp-d3/def2-tzvp | 1 |
| 170 | b3lyp/aug-cc-pvdz | 1 |
| 171 | b3lyp/lacv3p** | 1 |
| 172 | b3lyp/sddall | 1 |
| 173 | basal-mid | 1 |
| 174 | bcl-xl-bax-mediated | 1 |
| 175 | beta6 | 1 |
| 176 | between-physician | 1 |
| 177 | bhandh/aug-pcj-2 | 1 |
| 178 | bhandhlyp/6-311g | 1 |
| 179 | bhandhlyp/aug-cc-pvdz | 1 |
| 180 | binge-purging | 1 |
| 181 | butane-dione | 1 |
| 182 | casscf/caspt2 | 1 |
| 183 | cbf/dreb | 1 |
| 184 | cbf/dreb1 | 1 |
| 185 | ceftriaxone/ornidazole-group | 1 |
| 186 | cellular-molecular | 1 |
| 187 | cgmp-inhibitable | 1 |
| 188 | chan-vese | 1 |
| 189 | cleavage-site | 1 |
| 190 | coletivo | 1 |
| 191 | collagene | 1 |
| 192 | community-skills | 1 |
| 193 | continine | 1 |
| 194 | cosmochemical | 1 |
| 195 | course-3.67 | 1 |
| 196 | curve=21.7±13.8 | 1 |
| 197 | curve=220±209 | 1 |
| 198 | cynipoid | 1 |
| 199 | cyp12 | 1 |
| 200 | cyp6a | 1 |
| 201 | cyp6b | 1 |
| 202 | cyp75b | 1 |
| 203 | deep/middle | 1 |
| 204 | dha-high | 1 |
| 205 | drug-intake | 1 |
| 206 | eaf7 | 1 |
| 207 | ecap-based | 1 |
| 208 | electron-translucent | 1 |
| 209 | emberizinae | 1 |
| 210 | enacα | 1 |
| 211 | erythemotelangiectatic | 1 |
| 212 | escitalopram-group | 1 |
| 213 | ethnopsychogeriatric | 1 |
| 214 | expres- | 1 |
| 215 | fixed-low | 1 |
| 216 | free-virus | 1 |
| 217 | gamma-receptor | 1 |
| 218 | gbp/fmz/higher | 1 |
| 219 | gckiii | 1 |
| 220 | ghelin | 1 |
| 221 | glucocorticoid-receptor | 1 |
| 222 | glycotransferase | 1 |
| 223 | gsta4-4 | 1 |
| 224 | gurage | 1 |
| 225 | heaviest-weight | 1 |
| 226 | high-immediacy | 1 |
| 227 | highest-heat | 1 |
| 228 | highest-variability | 1 |
| 229 | hsp-70-positive | 1 |
| 230 | hypothalamuic | 1 |
| 231 | iiaa15g2r1 | 1 |
| 232 | iib3 | 1 |
| 233 | individual-social | 1 |
| 234 | infra-single-cell | 1 |
| 235 | intermediate-high-surgical-risk | 1 |
| 236 | intermediate-range | 1 |
| 237 | intra-field | 1 |
| 238 | ion-passing | 1 |
| 239 | iro-group | 1 |
| 240 | ivus-determined | 1 |
| 241 | kinetocardiogram | 1 |
| 242 | ksha5 | 1 |
| 243 | ladarwave | 1 |
| 244 | ld0 | 1 |
| 245 | low-sbp | 1 |
| 246 | lowest-accepted | 1 |
| 247 | lowest-observed-adverse-effect | 1 |
| 248 | lowest-use | 1 |
| 249 | m06-2x/aug-cc-pvdz | 1 |
| 250 | mcg3/3 | 1 |
| 251 | mean-per-patient | 1 |
| 252 | mid-endocardial | 1 |
| 253 | midheight | 1 |
| 254 | mothers-against-dpp | 1 |
| 255 | mpw1k/qzvpp | 1 |
| 256 | mpwb1k/6-311g** | 1 |
| 257 | mri-calculated | 1 |
| 258 | mrtv | 1 |
| 259 | multimilligram | 1 |
| 260 | ndh-h | 1 |
| 261 | needs/actions | 1 |
| 262 | neurolept/propofol/isoflurane | 1 |
| 263 | neuropeptide-y | 1 |
| 264 | next-higher | 1 |
| 265 | no-toxic | 1 |
| 266 | non-alert | 1 |
| 267 | nuog | 1 |
| 268 | oa-suppressed | 1 |
| 269 | on-current | 1 |
| 270 | organisational-institutional | 1 |
| 271 | orthoretrovirinae | 1 |
| 272 | p65-nf-κb | 1 |
| 273 | parajet | 1 |
| 274 | parvoririnae | 1 |
| 275 | parvulin | 1 |
| 276 | pbe0/def2-tzvpp | 1 |
| 277 | pd-endemic | 1 |
| 278 | periinfarction | 1 |
| 279 | ph-gel | 1 |
| 280 | phosphatide | 1 |
| 281 | phosphorylative | 1 |
| 282 | physical/atomic | 1 |
| 283 | pipette-tip | 1 |
| 284 | pkc-epsilon | 1 |
| 285 | pneumovirinae | 1 |
| 286 | poh1 | 1 |
| 287 | post‑transcriptional | 1 |
| 288 | pre-pvr | 1 |
| 289 | presmoking | 1 |
| 290 | primary-study | 1 |
| 291 | protease-insensitive | 1 |
| 292 | resident-day | 1 |
| 293 | rest-to-hyperemia | 1 |
| 294 | ri-cc2/aug-cc-pvdz | 1 |
| 295 | rivrt'-evaluated | 1 |
| 296 | second-highest | 1 |
| 297 | sertoli-step | 1 |
| 298 | setting/clinician | 1 |
| 299 | shot-noise-limited | 1 |
| 300 | siplizumab-treated | 1 |
| 301 | smoke-dependent | 1 |
| 302 | student/resident’s | 1 |
| 303 | sub-bleaching | 1 |
| 304 | subven-tricular | 1 |
| 305 | surfactant/detergent | 1 |
| 306 | t5-6 | 1 |
| 307 | tbx2 | 1 |
| 308 | tco-ne | 1 |
| 309 | thomas-fermi-dirac | 1 |
| 310 | three-normal | 1 |
| 311 | time-insulin | 1 |
| 312 | tranisizion | 1 |
| 313 | trans-metatarsal | 1 |
| 314 | under-curve | 1 |
| 315 | united-states | 1 |
| 316 | uv-initiating | 1 |
| 317 | vadose | 1 |
| 318 | vindoline-derived | 1 |
| 319 | who-pcdd/f-pcb-teq | 1 |
| 320 | wholesaler | 1 |
| 321 | within-physician | 1 |
| 322 | zinc-coordinating | 1 |
| 323 | α-tocopherol/lipid | 1 |
| 324 | α4β2α5-nachr | 1 |
| 325 | χmt | 1 |
| 326 | ≥6- | 1 |
| 1 | 'gray | 2 |
| 2 | 'intelligence | 1 |
| 3 | 'macular | 2 |
| 4 | -3826 | 4 |
| 5 | 0.05-alpha | 1 |
| 6 | 0.05mg/kg/day | 2 |
| 7 | 0.10-mg/kg/d | 1 |
| 8 | 0.4-g/kg | 3 |
| 9 | 0.5-mg-per-kilogram | 1 |
| 10 | 0.50-mg/kg | 1 |
| 11 | 0.8mg | 1 |
| 12 | 1.0-mg-per-kilogram | 1 |
| 13 | 1.0-microg/kg | 1 |
| 14 | 1.2-ml | 1 |
| 15 | 1.5+/-1.2 | 2 |
| 16 | 10.3mm | 1 |
| 17 | 100-mg/day | 1 |
| 18 | 100-mug | 1 |
| 19 | 1100-mbq | 1 |
| 20 | 12-μg | 1 |
| 21 | 15-micrograms | 1 |
| 22 | 16-g | 1 |
| 23 | 160-μg | 1 |
| 24 | 1600-mg | 2 |
| 25 | 2-g/day | 1 |
| 26 | 2.0-mg-per-kilogram | 1 |
| 27 | 2.89σ | 1 |
| 28 | 20-150-mg | 1 |
| 29 | 20-μg/kg | 1 |
| 30 | 200-mg/week | 1 |
| 31 | 22-mcg | 2 |
| 32 | 22-μg | 1 |
| 33 | 23k4 | 2 |
| 34 | 24-atom | 3 |
| 35 | 24-mg/day | 1 |
| 36 | 24-μg | 1 |
| 37 | 25-kbq/kg | 1 |
| 38 | 25-microgram | 1 |
| 39 | 3-9mg/kg | 1 |
| 40 | 3.1-mg | 1 |
| 41 | 3.9-g/d | 1 |
| 42 | 30-unit | 1 |
| 43 | 300-mg/week | 1 |
| 44 | 300-microg | 1 |
| 45 | 380-µg/ml | 1 |
| 46 | 4.8-g/d | 1 |
| 47 | 40-μg/kg | 1 |
| 48 | 400-mg-qd | 1 |
| 49 | 400-mgi/kg | 1 |
| 50 | 420-µg/ml | 1 |
| 51 | 44-mcg | 1 |
| 52 | 44-μg | 1 |
| 53 | 45-μg/week | 1 |
| 54 | 49-μg | 2 |
| 55 | 5,5'-disubstituted | 2 |
| 56 | 5-ht₃b | 1 |
| 57 | 50-db | 1 |
| 58 | 50-kbq/kg | 1 |
| 59 | 50-ng | 1 |
| 60 | 500-nmol | 2 |
| 61 | 5th-percentile | 1 |
| 62 | 60-minute/week | 1 |
| 63 | 60-μg/kg | 1 |
| 64 | 7.5-g | 2 |
| 65 | 7777 | 1 |
| 66 | 800-microg | 2 |
| 67 | 800-µg | 1 |
| 68 | 9-mg/d | 1 |
| 69 | 9-mg/kg | 1 |
| 70 | 90-μg/week | 1 |
| 71 | 90mg/day | 1 |
| 72 | 95th-percentile | 1 |
| 73 | 9mg/kg | 2 |
| 74 | a4β2 | 1 |
| 75 | ahr-agonists | 2 |
| 76 | alerted/reaching | 1 |
| 77 | alpha-adrenoceptor-like | 1 |
| 78 | alpha2delta | 2 |
| 79 | alpha2delta-1 | 1 |
| 80 | amol-fmol | 1 |
| 81 | anti-epsilon | 1 |
| 82 | anti-eta | 1 |
| 83 | anti-zeta | 1 |
| 84 | apamin-blockable | 1 |
| 85 | arb-fdc | 1 |
| 86 | asthma-mortality | 1 |
| 87 | b*44:02 | 1 |
| 88 | b3lyp-d3/def2-tzvp | 1 |
| 89 | b3lyp-td | 2 |
| 90 | b3lyp/6-311++g** | 2 |
| 91 | b3lyp/6-311+g**//b3lyp/6-31+g* | 2 |
| 92 | b3lyp/aug-cc-pvdz | 1 |
| 93 | b3lyp/lacv3p** | 1 |
| 94 | b3lyp/sddall | 1 |
| 95 | basal-mid | 1 |
| 96 | bcl-xl-bax-mediated | 1 |
| 97 | beta6 | 1 |
| 98 | between-physician | 1 |
| 99 | bhandh/aug-pcj-2 | 1 |
| 100 | bhandhlyp/6-311g | 1 |
| 101 | bhandhlyp/aug-cc-pvdz | 1 |
| 102 | binge-purging | 1 |
| 103 | blood-pool-corrected | 2 |
| 104 | brillouin | 15 |
| 105 | butane-dione | 1 |
| 106 | bølling-allerød | 5 |
| 107 | c3-c4 | 12 |
| 108 | casscf/caspt2 | 1 |
| 109 | cbf/dreb | 1 |
| 110 | cbf/dreb1 | 1 |
| 111 | ceftriaxone/ornidazole-group | 1 |
| 112 | cellular-molecular | 1 |
| 113 | cell’s | 2 |
| 114 | cgmp-inhibitable | 1 |
| 115 | chan-vese | 1 |
| 116 | cheongdang | 2 |
| 117 | cleavage-site | 1 |
| 118 | coletivo | 1 |
| 119 | collagene | 1 |
| 120 | community-skills | 1 |
| 121 | continine | 1 |
| 122 | coral-dinoflagellate | 2 |
| 123 | cosmochemical | 1 |
| 124 | course-3.67 | 1 |
| 125 | cpg-slope | 6 |
| 126 | cross-plane | 7 |
| 127 | curve=21.7±13.8 | 1 |
| 128 | curve=220±209 | 1 |
| 129 | cynipoid | 1 |
| 130 | cyp12 | 1 |
| 131 | cyp6a | 1 |
| 132 | cyp6b | 1 |
| 133 | cyp75a | 2 |
| 134 | cyp75b | 1 |
| 135 | deep/middle | 1 |
| 136 | delipidated | 2 |
| 137 | densu | 2 |
| 138 | dha-high | 1 |
| 139 | drug-intake | 1 |
| 140 | e1α | 2 |
| 141 | eaf7 | 1 |
| 142 | ecap-based | 1 |
| 143 | ed₅₀ | 16 |
| 144 | electron-translucent | 1 |
| 145 | emberizinae | 1 |
| 146 | enacα | 1 |
| 147 | endotoxemia-induced | 3 |
| 148 | erythemotelangiectatic | 1 |
| 149 | escitalopram-group | 1 |
| 150 | ethnopsychogeriatric | 1 |
| 151 | euphotic | 4 |
| 152 | expres- | 1 |
| 153 | farman | 2 |
| 154 | femtomole | 2 |
| 155 | first-limiting | 3 |
| 156 | fixed-low | 1 |
| 157 | fl-ghr | 2 |
| 158 | free-virus | 1 |
| 159 | gamma-receptor | 1 |
| 160 | gbp/fmz/higher | 1 |
| 161 | gckiii | 1 |
| 162 | ghelin | 1 |
| 163 | glucocorticoid-receptor | 1 |
| 164 | glycotransferase | 1 |
| 165 | gsta4-4 | 1 |
| 166 | gurage | 1 |
| 167 | heaviest-weight | 1 |
| 168 | high-immediacy | 1 |
| 169 | highest | 11,480 |
| 170 | highest-heat | 1 |
| 171 | highest-use | 2 |
| 172 | highest-variability | 1 |
| 173 | hipec-mediated | 2 |
| 174 | hospital-facility | 2 |
| 175 | hsp-70-positive | 1 |
| 176 | hsp110/sse | 3 |
| 177 | hypothalamuic | 1 |
| 178 | iiaa15g2r1 | 1 |
| 179 | iib3 | 1 |
| 180 | immunotype | 4 |
| 181 | in-tegration | 2 |
| 182 | individual-social | 1 |
| 183 | indole-3-carbinol-induced | 3 |
| 184 | infra-single-cell | 1 |
| 185 | interdiffusion | 4 |
| 186 | intermediate-high-surgical-risk | 1 |
| 187 | intermediate-range | 1 |
| 188 | intra-field | 1 |
| 189 | ion-passing | 1 |
| 190 | iro-group | 1 |
| 191 | itz-hpmcas | 2 |
| 192 | ivus-determined | 1 |
| 193 | kaplan-meier-predicted | 2 |
| 194 | kinetocardiogram | 1 |
| 195 | ksha5 | 1 |
| 196 | ladarwave | 1 |
| 197 | larmor | 3 |
| 198 | ld0 | 1 |
| 199 | low-sbp | 1 |
| 200 | lowest | 4,890 |
| 201 | lowest-accepted | 1 |
| 202 | lowest-observed-adverse-effect | 1 |
| 203 | lowest-use | 1 |
| 204 | lv-pv | 7 |
| 205 | m06-2x/aug-cc-pvdz | 1 |
| 206 | mcg3/3 | 1 |
| 207 | mdr1a | 2 |
| 208 | mean-per-patient | 1 |
| 209 | median-adjusted | 2 |
| 210 | medif | 7 |
| 211 | melastatin-related | 2 |
| 212 | mglu2/3r | 3 |
| 213 | mid-endocardial | 1 |
| 214 | mid-papillary | 5 |
| 215 | mid-to-peripheral | 2 |
| 216 | midheight | 1 |
| 217 | minus-hybrid | 2 |
| 218 | mothers-against-dpp | 1 |
| 219 | mp2/aug-cc-pvtz | 3 |
| 220 | mpw1k/qzvpp | 1 |
| 221 | mpwb1k/6-311g** | 1 |
| 222 | mri-calculated | 1 |
| 223 | mrtv | 1 |
| 224 | multimilligram | 1 |
| 225 | ndh-h | 1 |
| 226 | needs/actions | 1 |
| 227 | neuroenergetic | 2 |
| 228 | neurolept/propofol/isoflurane | 1 |
| 229 | neuropeptide-y | 1 |
| 230 | next-higher | 1 |
| 231 | no-observed-effect | 4 |
| 232 | no-toxic | 1 |
| 233 | non-alert | 1 |
| 234 | nuog | 1 |
| 235 | oa-suppressed | 1 |
| 236 | on-current | 1 |
| 237 | optetrak | 2 |
| 238 | organisational-institutional | 1 |
| 239 | orthoretrovirinae | 1 |
| 240 | p65-nf-κb | 1 |
| 241 | pam50-based | 2 |
| 242 | parajet | 1 |
| 243 | part-per-billion | 3 |
| 244 | parvoririnae | 1 |
| 245 | parvulin | 1 |
| 246 | pbe0/def2-tzvpp | 1 |
| 247 | pd-endemic | 1 |
| 248 | periinfarction | 1 |
| 249 | ph-gel | 1 |
| 250 | phosphatide | 1 |
| 251 | phosphorylative | 1 |
| 252 | physical/atomic | 1 |
| 253 | physician-specified | 2 |
| 254 | pipette-tip | 1 |
| 255 | pkc-epsilon | 1 |
| 256 | pneumovirinae | 1 |
| 257 | poh1 | 1 |
| 258 | post-combustion | 7 |
| 259 | post-fibroscan | 3 |
| 260 | post-to-pre-urinary | 2 |
| 261 | post‑transcriptional | 1 |
| 262 | pre-pvr | 1 |
| 263 | preresponse | 5 |
| 264 | presmoking | 1 |
| 265 | primary-study | 1 |
| 266 | protease-insensitive | 1 |
| 267 | psl-induced | 2 |
| 268 | quasi-steady-state | 6 |
| 269 | region-level | 2 |
| 270 | resident-day | 1 |
| 271 | rest-to-hyperemia | 1 |
| 272 | ri-cc2/aug-cc-pvdz | 1 |
| 273 | rivrt'-evaluated | 1 |
| 274 | rs11466285 | 3 |
| 275 | s2p | 2 |
| 276 | second-highest | 1 |
| 277 | sertoli-step | 1 |
| 278 | setting/clinician | 1 |
| 279 | sgc-α1 | 4 |
| 280 | shot-noise-limited | 1 |
| 281 | siplizumab-treated | 1 |
| 282 | slowest | 66 |
| 283 | smoke-dependent | 1 |
| 284 | spounavirinae | 2 |
| 285 | squid-vibrio | 2 |
| 286 | student/resident’s | 1 |
| 287 | sub-bleaching | 1 |
| 288 | subgranular | 9 |
| 289 | subven-tricular | 1 |
| 290 | subventricular | 14 |
| 291 | surfactant/detergent | 1 |
| 292 | t/h12.5 | 4 |
| 293 | t5-6 | 1 |
| 294 | t6-t4 | 3 |
| 295 | tbx2 | 1 |
| 296 | tco-ne | 1 |
| 297 | tensin | 49 |
| 298 | thomas-fermi-dirac | 1 |
| 299 | three-normal | 1 |
| 300 | time-insulin | 1 |
| 301 | tiss-28 | 2 |
| 302 | tranisizion | 1 |
| 303 | trans-metatarsal | 1 |
| 304 | trinational | 2 |
| 305 | ttgghi | 3 |
| 306 | under-curve | 1 |
| 307 | undersaturated | 2 |
| 308 | united-states | 1 |
| 309 | uv-initiating | 1 |
| 310 | vadose | 1 |
| 311 | vindoline-derived | 1 |
| 312 | visian | 2 |
| 313 | who-pcdd/f-pcb-teq | 1 |
| 314 | whole-year | 2 |
| 315 | wholesaler | 1 |
| 316 | within-assay | 2 |
| 317 | within-each-population | 2 |
| 318 | within-physician | 1 |
| 319 | within-school | 3 |
| 320 | zinc-coordinating | 1 |
| 321 | α-ktx15 | 2 |
| 322 | α-tocopherol/lipid | 1 |
| 323 | α4β2α5-nachr | 1 |
| 324 | β3a | 3 |
| 325 | χmt | 1 |
| 326 | ≥6- | 1 |
| 1 | b3lyp/6-311++g** | 2 |
| 2 | mpwb1k/6-311g** | 1 |
| 3 | b3lyp/lacv3p** | 1 |
| 4 | b3lyp/6-311+g**//b3lyp/6-31+g* | 2 |
| 5 | ≥6- | 1 |
| 6 | expres- | 1 |
| 7 | ld0 | 1 |
| 8 | alpha2delta-1 | 1 |
| 9 | cbf/dreb1 | 1 |
| 10 | poh1 | 1 |
| 11 | iiaa15g2r1 | 1 |
| 12 | sgc-α1 | 4 |
| 13 | bhandh/aug-pcj-2 | 1 |
| 14 | 1.5+/-1.2 | 2 |
| 15 | b*44:02 | 1 |
| 16 | cyp12 | 1 |
| 17 | casscf/caspt2 | 1 |
| 18 | tbx2 | 1 |
| 19 | a4β2 | 1 |
| 20 | mcg3/3 | 1 |
| 21 | iib3 | 1 |
| 22 | gsta4-4 | 1 |
| 23 | c3-c4 | 12 |
| 24 | 23k4 | 2 |
| 25 | t6-t4 | 3 |
| 26 | t/h12.5 | 4 |
| 27 | α-ktx15 | 2 |
| 28 | rs11466285 | 3 |
| 29 | ksha5 | 1 |
| 30 | t5-6 | 1 |
| 31 | -3826 | 4 |
| 32 | beta6 | 1 |
| 33 | course-3.67 | 1 |
| 34 | 7777 | 1 |
| 35 | eaf7 | 1 |
| 36 | curve=21.7±13.8 | 1 |
| 37 | tiss-28 | 2 |
| 38 | curve=220±209 | 1 |
| 39 | mdr1a | 2 |
| 40 | β3a | 3 |
| 41 | cyp75a | 2 |
| 42 | cyp6a | 1 |
| 43 | 0.05-alpha | 1 |
| 44 | rest-to-hyperemia | 1 |
| 45 | anti-eta | 1 |
| 46 | anti-zeta | 1 |
| 47 | alpha2delta | 2 |
| 48 | cyp75b | 1 |
| 49 | cyp6b | 1 |
| 50 | 50-db | 1 |
| 51 | cbf/dreb | 1 |
| 52 | 5-ht₃b | 1 |
| 53 | p65-nf-κb | 1 |
| 54 | thomas-fermi-dirac | 1 |
| 55 | arb-fdc | 1 |
| 56 | pd-endemic | 1 |
| 57 | physical/atomic | 1 |
| 58 | ethnopsychogeriatric | 1 |
| 59 | erythemotelangiectatic | 1 |
| 60 | neuroenergetic | 2 |
| 61 | euphotic | 4 |
| 62 | hypothalamuic | 1 |
| 63 | no-toxic | 1 |
| 64 | 4.8-g/d | 1 |
| 65 | 3.9-g/d | 1 |
| 66 | 0.10-mg/kg/d | 1 |
| 67 | 9-mg/d | 1 |
| 68 | endotoxemia-induced | 3 |
| 69 | indole-3-carbinol-induced | 3 |
| 70 | psl-induced | 2 |
| 71 | physician-specified | 2 |
| 72 | ivus-determined | 1 |
| 73 | pam50-based | 2 |
| 74 | ecap-based | 1 |
| 75 | oa-suppressed | 1 |
| 76 | delipidated | 2 |
| 77 | siplizumab-treated | 1 |
| 78 | hipec-mediated | 2 |
| 79 | bcl-xl-bax-mediated | 1 |
| 80 | melastatin-related | 2 |
| 81 | mri-calculated | 1 |
| 82 | undersaturated | 2 |
| 83 | rivrt'-evaluated | 1 |
| 84 | blood-pool-corrected | 2 |
| 85 | kaplan-meier-predicted | 2 |
| 86 | shot-noise-limited | 1 |
| 87 | lowest-accepted | 1 |
| 88 | median-adjusted | 2 |
| 89 | 5,5'-disubstituted | 2 |
| 90 | vindoline-derived | 1 |
| 91 | basal-mid | 1 |
| 92 | cynipoid | 1 |
| 93 | α-tocopherol/lipid | 1 |
| 94 | minus-hybrid | 2 |
| 95 | intra-field | 1 |
| 96 | 400-mg-qd | 1 |
| 97 | b3lyp-td | 2 |
| 98 | bølling-allerød | 5 |
| 99 | parvoririnae | 1 |
| 100 | spounavirinae | 2 |
| 101 | pneumovirinae | 1 |
| 102 | orthoretrovirinae | 1 |
| 103 | emberizinae | 1 |
| 104 | 'intelligence | 1 |
| 105 | phosphatide | 1 |
| 106 | gurage | 1 |
| 107 | intermediate-range | 1 |
| 108 | drug-intake | 1 |
| 109 | alpha-adrenoceptor-like | 1 |
| 110 | apamin-blockable | 1 |
| 111 | cgmp-inhibitable | 1 |
| 112 | deep/middle | 1 |
| 113 | 5th-percentile | 1 |
| 114 | 95th-percentile | 1 |
| 115 | femtomole | 2 |
| 116 | tco-ne | 1 |
| 117 | cross-plane | 7 |
| 118 | neurolept/propofol/isoflurane | 1 |
| 119 | collagene | 1 |
| 120 | continine | 1 |
| 121 | butane-dione | 1 |
| 122 | cpg-slope | 6 |
| 123 | immunotype | 4 |
| 124 | glycotransferase | 1 |
| 125 | chan-vese | 1 |
| 126 | preresponse | 5 |
| 127 | vadose | 1 |
| 128 | hsp110/sse | 3 |
| 129 | highest-use | 2 |
| 130 | lowest-use | 1 |
| 131 | coral-dinoflagellate | 2 |
| 132 | quasi-steady-state | 6 |
| 133 | cleavage-site | 1 |
| 134 | ladarwave | 1 |
| 135 | phosphorylative | 1 |
| 136 | protease-insensitive | 1 |
| 137 | hsp-70-positive | 1 |
| 138 | under-curve | 1 |
| 139 | medif | 7 |
| 140 | 7.5-g | 2 |
| 141 | 16-g | 1 |
| 142 | bhandhlyp/6-311g | 1 |
| 143 | 22-mcg | 2 |
| 144 | 44-mcg | 1 |
| 145 | 0.4-g/kg | 3 |
| 146 | 0.50-mg/kg | 1 |
| 147 | 9-mg/kg | 1 |
| 148 | 9mg/kg | 2 |
| 149 | 3-9mg/kg | 1 |
| 150 | 1.0-microg/kg | 1 |
| 151 | 20-μg/kg | 1 |
| 152 | 40-μg/kg | 1 |
| 153 | 60-μg/kg | 1 |
| 154 | 400-mgi/kg | 1 |
| 155 | 50-kbq/kg | 1 |
| 156 | 25-kbq/kg | 1 |
| 157 | 1600-mg | 2 |
| 158 | 20-150-mg | 1 |
| 159 | 3.1-mg | 1 |
| 160 | 0.8mg | 1 |
| 161 | 50-ng | 1 |
| 162 | cheongdang | 2 |
| 163 | binge-purging | 1 |
| 164 | sub-bleaching | 1 |
| 165 | alerted/reaching | 1 |
| 166 | presmoking | 1 |
| 167 | ion-passing | 1 |
| 168 | uv-initiating | 1 |
| 169 | zinc-coordinating | 1 |
| 170 | first-limiting | 3 |
| 171 | 300-microg | 1 |
| 172 | 800-microg | 2 |
| 173 | nuog | 1 |
| 174 | 100-mug | 1 |
| 175 | 800-µg | 1 |
| 176 | 160-μg | 1 |
| 177 | 12-μg | 1 |
| 178 | 22-μg | 1 |
| 179 | 24-μg | 1 |
| 180 | 44-μg | 1 |
| 181 | 49-μg | 2 |
| 182 | ndh-h | 1 |
| 183 | dha-high | 1 |
| 184 | ttgghi | 3 |
| 185 | gckiii | 1 |
| 186 | optetrak | 2 |
| 187 | 60-minute/week | 1 |
| 188 | 200-mg/week | 1 |
| 189 | 300-mg/week | 1 |
| 190 | 90-μg/week | 1 |
| 191 | 45-μg/week | 1 |
| 192 | intermediate-high-surgical-risk | 1 |
| 193 | cosmochemical | 1 |
| 194 | individual-social | 1 |
| 195 | mid-endocardial | 1 |
| 196 | three-normal | 1 |
| 197 | trinational | 2 |
| 198 | post‑transcriptional | 1 |
| 199 | organisational-institutional | 1 |
| 200 | mid-to-peripheral | 2 |
| 201 | trans-metatarsal | 1 |
| 202 | ph-gel | 1 |
| 203 | region-level | 2 |
| 204 | b3lyp/sddall | 1 |
| 205 | infra-single-cell | 1 |
| 206 | 1.2-ml | 1 |
| 207 | 420-µg/ml | 1 |
| 208 | 380-µg/ml | 1 |
| 209 | amol-fmol | 1 |
| 210 | 500-nmol | 2 |
| 211 | within-school | 3 |
| 212 | multimilligram | 1 |
| 213 | kinetocardiogram | 1 |
| 214 | 1.0-mg-per-kilogram | 1 |
| 215 | 2.0-mg-per-kilogram | 1 |
| 216 | 0.5-mg-per-kilogram | 1 |
| 217 | 25-microgram | 1 |
| 218 | 10.3mm | 1 |
| 219 | 24-atom | 3 |
| 220 | post-fibroscan | 3 |
| 221 | setting/clinician | 1 |
| 222 | between-physician | 1 |
| 223 | within-physician | 1 |
| 224 | visian | 2 |
| 225 | farman | 2 |
| 226 | ghelin | 1 |
| 227 | time-insulin | 1 |
| 228 | parvulin | 1 |
| 229 | tensin | 49 |
| 230 | brillouin | 15 |
| 231 | part-per-billion | 3 |
| 232 | interdiffusion | 4 |
| 233 | within-each-population | 2 |
| 234 | in-tegration | 2 |
| 235 | periinfarction | 1 |
| 236 | post-combustion | 7 |
| 237 | tranisizion | 1 |
| 238 | pkc-epsilon | 1 |
| 239 | anti-epsilon | 1 |
| 240 | squid-vibrio | 2 |
| 241 | coletivo | 1 |
| 242 | s2p | 2 |
| 243 | low-sbp | 1 |
| 244 | sertoli-step | 1 |
| 245 | pipette-tip | 1 |
| 246 | mothers-against-dpp | 1 |
| 247 | mpw1k/qzvpp | 1 |
| 248 | pbe0/def2-tzvpp | 1 |
| 249 | ceftriaxone/ornidazole-group | 1 |
| 250 | escitalopram-group | 1 |
| 251 | iro-group | 1 |
| 252 | b3lyp-d3/def2-tzvp | 1 |
| 253 | 1100-mbq | 1 |
| 254 | who-pcdd/f-pcb-teq | 1 |
| 255 | mglu2/3r | 3 |
| 256 | whole-year | 2 |
| 257 | 'macular | 2 |
| 258 | cellular-molecular | 1 |
| 259 | subven-tricular | 1 |
| 260 | subventricular | 14 |
| 261 | subgranular | 9 |
| 262 | next-higher | 1 |
| 263 | gbp/fmz/higher | 1 |
| 264 | wholesaler | 1 |
| 265 | α4β2α5-nachr | 1 |
| 266 | fl-ghr | 2 |
| 267 | larmor | 3 |
| 268 | gamma-receptor | 1 |
| 269 | glucocorticoid-receptor | 1 |
| 270 | pre-pvr | 1 |
| 271 | itz-hpmcas | 2 |
| 272 | united-states | 1 |
| 273 | community-skills | 1 |
| 274 | 15-micrograms | 1 |
| 275 | needs/actions | 1 |
| 276 | ahr-agonists | 2 |
| 277 | free-virus | 1 |
| 278 | cell’s | 2 |
| 279 | student/resident’s | 1 |
| 280 | highest-heat | 1 |
| 281 | no-observed-effect | 4 |
| 282 | lowest-observed-adverse-effect | 1 |
| 283 | parajet | 1 |
| 284 | midheight | 1 |
| 285 | heaviest-weight | 1 |
| 286 | 30-unit | 1 |
| 287 | χmt | 1 |
| 288 | electron-translucent | 1 |
| 289 | smoke-dependent | 1 |
| 290 | surfactant/detergent | 1 |
| 291 | mean-per-patient | 1 |
| 292 | on-current | 1 |
| 293 | non-alert | 1 |
| 294 | highest | 11,480 |
| 295 | second-highest | 1 |
| 296 | lowest | 4,890 |
| 297 | slowest | 66 |
| 298 | densu | 2 |
| 299 | lv-pv | 7 |
| 300 | mrtv | 1 |
| 301 | fixed-low | 1 |
| 302 | neuropeptide-y | 1 |
| 303 | resident-day | 1 |
| 304 | 2-g/day | 1 |
| 305 | 0.05mg/kg/day | 2 |
| 306 | 100-mg/day | 1 |
| 307 | 24-mg/day | 1 |
| 308 | 90mg/day | 1 |
| 309 | 'gray | 2 |
| 310 | within-assay | 2 |
| 311 | high-immediacy | 1 |
| 312 | primary-study | 1 |
| 313 | mid-papillary | 5 |
| 314 | post-to-pre-urinary | 2 |
| 315 | asthma-mortality | 1 |
| 316 | highest-variability | 1 |
| 317 | hospital-facility | 2 |
| 318 | ri-cc2/aug-cc-pvdz | 1 |
| 319 | b3lyp/aug-cc-pvdz | 1 |
| 320 | bhandhlyp/aug-cc-pvdz | 1 |
| 321 | m06-2x/aug-cc-pvdz | 1 |
| 322 | mp2/aug-cc-pvtz | 3 |
| 323 | ed₅₀ | 16 |
| 324 | 2.89σ | 1 |
| 325 | e1α | 2 |
| 326 | enacα | 1 |